HBOT for dogs/pets: veterinary evidence

Hyperbaric oxygen therapy (HBOT) has moved from human wound clinics into veterinary practice, and a growing number of clinics now offer it for dogs, cats, and horses. The pitch is appealing: put a sick or injured animal in a pressurized chamber, flood its tissues with oxygen, and speed up healing. But the honest picture is more cautious than the marketing. No randomized controlled trial has yet proven that HBOT helps dogs or cats with any specific condition, and most of what clinics claim is borrowed from human medicine, lab models, or case reports.

This atlas walks through how HBOT is supposed to work in animals, what the real veterinary studies have and haven't shown, where the evidence is weak, what it costs, and how to think about safety. The goal is to give pet owners and curious readers a sober, evidence-graded view so you can ask better questions before spending money on a therapy that sits, for now, in the experimental zone.

How HBOT Is Supposed to Work in Animals

The basic idea is the same in animals as in people. The patient breathes near-100% oxygen inside a sealed chamber pressurized above sea level, usually to about 2 atmospheres absolute (2 ATA). At that pressure, far more oxygen dissolves directly into the blood plasma instead of riding only on red blood cells. The result is a temporary, large jump in how much oxygen reaches the tissues.

That extra oxygen drives several proposed effects. The veterinary literature describes the main mechanisms this way:

• Deeper oxygen diffusion. Under high pressure, oxygen can spread farther from blood vessels into starved tissue. One veterinary review notes that at 3 ATA, oxygen can diffuse up to four times the normal distance from capillaries, which matters in swollen or crushed tissue where blood flow is blocked.
• Less swelling. HBOT causes healthy blood vessels to narrow slightly (vasoconstriction), which can reduce fluid buildup and edema in injured areas without starving the tissue of oxygen.
• New blood vessel growth. Repeated sessions appear to stimulate angiogenesis, the budding of new vessels, partly by raising growth factors like VEGF and mobilizing stem cells. A veterinary rationale paper reports that a single two-hour exposure roughly doubles circulating CD34+ progenitor stem cells.
• Fighting infection. High oxygen levels are toxic to anaerobic bacteria, which lack the enzymes to survive a hyperoxic environment, and can boost the killing power of certain white blood cells and antibiotics.

These mechanisms are real and well documented in laboratory and human research. The catch is that a plausible mechanism is not the same as a proven clinical benefit in your dog. Much of what follows is the gap between the two.

It's worth dwelling on why that gap exists, because it's the heart of the whole debate. A mechanism explains how a therapy could help. A clinical trial measures whether it actually does. The history of medicine is littered with treatments that made perfect biological sense and then failed when finally tested against a control group. Oxygen reaching starved tissue sounds unambiguously good, but living systems are full of feedback loops. Too much oxygen generates reactive oxygen species that can damage cells. The body's response to injury is tightly orchestrated, and flooding it with oxygen at the wrong moment may help, do nothing, or interfere. The only way to know which happens in a real dog with a real disease is to run the experiment with a comparison group. In veterinary HBOT, that experiment largely hasn't been run.

A second complication is dosing. In human hyperbaric medicine, the approved indications come with specific, validated protocols: a set pressure, a set duration, a set number of sessions. Veterinary protocols are mostly imported wholesale from those human schedules or adjusted by clinical instinct, without species-specific dose-finding. A dog is not a small human. Metabolic rate, body size, oxygen tolerance, and the threshold for oxygen toxicity all differ, which is exactly why, as you'll see in the safety section, dogs seize at higher rates than people do under similar conditions.

The Honest Evidence Picture: No RCTs Yet

Here is the single most important fact in this entire topic. As of 2026, there are no published randomized, controlled clinical trials showing that HBOT improves outcomes in dogs or cats for any specific naturally occurring disease. The therapy is in routine clinical use at some referral hospitals, but its adoption runs well ahead of its proof.

The veterinary evidence that does exist falls into three buckets: safety studies, retrospective chart reviews, and extrapolation from human and lab data. None of these can tell you whether an animal recovered because of HBOT or simply alongside it. Without a control group, you cannot separate the therapy from the body's own healing, the other treatments given at the same time, or selection bias in which patients get referred.

A skeptical veterinary reviewer put it bluntly: there is virtually no clinical trial data in companion animals to support HBOT for specific indications, which means it should essentially be considered experimental even where it is offered confidently. That assessment still holds.

Evidence grade by condition

The table below grades the evidence for the most commonly marketed canine and feline uses. "Mechanistic only" means the rationale rests on lab or human data, not target-species outcomes. Grades are deliberately conservative.

If a clinic presents any of these as established or proven for animals, that is overstating the science.

What the Real Veterinary Studies Found

A handful of studies form the backbone of the veterinary HBOT literature. They are worth understanding in detail because they are mostly about safety and usage patterns, not whether the therapy works.

The largest dataset: 2,792 treatment sessions

The biggest veterinary HBOT study to date is a retrospective analysis of 2,792 treatment sessions delivered to 576 animals at one referral center: 542 dogs (94.1%), 24 cats (4.2%), and 10 pocket pets or exotics (1.7%). Most sessions (88.5%) used 2 ATA, with about 15 minutes to pressurize, 45 minutes at pressure, and a gradual decompression.

The breakdown of why animals were treated tells you how the therapy is actually being used in practice:

Crucially, this study reports what conditions were treated and how often adverse events occurred — it does not, and cannot, tell you whether treated animals did better than untreated ones. It is an exposure-and-safety study, not an efficacy study. The authors themselves called for prospective trials to evaluate specific indications.

What this dataset is genuinely useful for is mapping the real-world veterinary HBOT market. It shows that the therapy is overwhelmingly a dog treatment, that neurologic cases drive most of the volume, and that it lives at referral and specialty hospitals rather than general practice. That matters for owners: if your regular vet doesn't offer it, you're typically being referred to a center that has invested in an expensive chamber and has a financial interest in using it. That isn't a reason to assume bad faith, but it is a reason to ask hard questions about whether the recommendation is evidence-driven or equipment-driven.

The safety trial: well tolerated, no major events

A prospective clinical trial in the Journal of the American Animal Hospital Association evaluated 230 hyperbaric treatments in 78 dogs and 12 cats with various naturally occurring conditions, using 2 ATA for 45 or 60 minutes in a monoplace chamber. No major adverse effects were recorded. There were 76 minor adverse effects, none judged clinically significant. The conclusion was that HBOT was well tolerated.

Again, note the framing. "Well tolerated" answers is it safe enough to use, not does it help. Both studies are reassuring on safety and silent on efficacy.

Spinal cord injury and IVDD

Intervertebral disc disease (IVDD) and spinal cord injury are among the most common reasons dogs are referred for HBOT. A 2020 review of emerging therapies for acute canine IVDD found only limited experimental evidence suggesting possible benefit versus untreated controls in lab models, with no additive effect when combined with DMSO, and explicitly no reports in dogs with naturally occurring disc herniation. In its words, HBOT is used in clinical cases by some veterinarians despite the absence of clinical trials. That is the textbook definition of an experimental therapy in routine use.

HBOT in Horses and Exotics

Horses are the other major veterinary HBOT market, often tied to tendon and ligament injuries, wounds, and rehabilitation in performance animals. The evidence here is, if anything, thinner than for dogs.

A clinical review in Veterinary Clinics of North America: Equine Practice and other appraisals make the same point repeatedly: equine HBOT data come mainly from anecdotal, client-driven, case-based reports rather than controlled studies. Many equine practitioners remain skeptical for exactly this reason. There are documented uses for wounds, cellulitis, osteomyelitis, and some neurologic problems, but documented use is not documented benefit.

Exotic and pocket pets make up a tiny fraction of treated animals (about 1.7% in the largest dataset), and the evidence base for them is essentially individual case reports. Extra caution is warranted in small species, where chamber environments and oxygen toxicity thresholds are even less studied.

Safety: Real Risks, Mostly Manageable

The safety story is the strongest part of the veterinary HBOT evidence, and it is genuinely reassuring when the therapy is done by trained staff in a properly built chamber. Serious harm is uncommon, but it is not zero, and animals cannot tell you when their ears hurt.

The two main risks are oxygen toxicity (mainly affecting the central nervous system as seizures) and barotrauma (pressure injury, most often to the ears or lungs).

Two risk factors raised the odds of a seizure in dogs: age over six years (about 4.6 times higher odds) and female sex (about 2.4 times higher odds). The seizure rate in dogs (0.7% per session) is notably higher than the rate reported in humans (roughly 0.002–0.035%), which the authors attribute partly to dogs' higher metabolic rates. That gap is a reason to take dosing and monitoring seriously, not to assume the human safety record transfers directly.

To put the numbers in perspective: 0.7% per session sounds small, but a typical course might be ten or twenty sessions, so the cumulative chance an individual dog experiences at least one seizure event across a full course is meaningfully higher than any single session implies. In the large dataset, 3.5% of all dogs treated had at least one CNS oxygen-toxicity event. The reassuring part is that every one of those dogs recovered once the pressure was reduced, with no reported lasting harm. The concerning part is that a seizure inside a sealed monoplace chamber is a frightening event that staff cannot immediately intervene on, which is precisely why continuous monitoring and a clear decompression plan are non-negotiable.

Barotrauma deserves its own note because it is almost certainly underreported in animals. In people, ear pain during compression is the single most common HBOT side effect, and patients learn to clear their ears. A dog can't be told to swallow or yawn on cue, and it can't report that its ears hurt. Signs like head shaking, pawing at the face, or distress during the pressurization phase may be the only clues. Slow, careful compression and decompression are the main defenses, and an animal with a recent ear infection or upper-airway problem may not be a good candidate at all.

Practical safety implications:

• Most veterinary chambers are monoplace (one patient), so a seizing animal cannot be physically reached until pressure comes down. Staff must monitor continuously.
• The chamber should be a purpose-built veterinary (Class C) pressure vessel meeting recognized engineering standards, not a repurposed human acrylic unit or a soft "mild HBOT" bag.
• Owners should be told about oxygen-toxicity and barotrauma risk before each session, and animals with seizure history, certain lung conditions, or recent ear problems deserve extra scrutiny.

A note on regulation: hyperbaric chambers used on animals are classified for veterinary use, but HBOT for a specific animal disease is not an FDA-approved indication the way some human uses are. Offering it is legal; calling it FDA-approved for your dog's condition is misleading.

Comparisons and Alternatives

HBOT is rarely the only option, and for most conditions where it's offered there are better-studied, cheaper alternatives. It is best understood as a possible adjunct, not a replacement for standard care.

• For wounds: Good surgical debridement, appropriate antibiotics, modern dressings, and sometimes cold laser therapy all have their own (also imperfect) evidence and far lower cost. HBOT might be considered for stubborn, oxygen-starved wounds that aren't healing with standard care.
• For IVDD and spinal injury: Surgery (for surgical candidates), strict rest, pain control, and physical rehabilitation remain the standard of care with the most support. HBOT, if used, is an unproven add-on.
• For "recovery" and wellness: There is no good reason to choose HBOT over rest, nutrition, and conventional rehab for healthy or mildly injured animals. The wellness framing has essentially no veterinary evidence behind it.

If you're weighing HBOT against other options, it can help to read how the human evidence is graded, since so much of the veterinary rationale is borrowed from it. Our deep dives on HBOT wound healing clinical evidence and how HBOT works: the complete science lay out where the human data is strong versus thin.

Who It Might Be Reasonable For

Given the evidence, a sober view is that HBOT in animals is most defensible as an adjunct in specific, hard-to-heal situations handled by a referral hospital with trained hyperbaric staff. That might include severe non-healing or infected wounds, certain crush or degloving injuries, compromised skin grafts or flaps, or select neurologic emergencies, always layered on top of standard treatment, never instead of it.

It is hardest to justify for routine recovery, general wellness, athletic "performance," chronic conditions with no plausible oxygen-deficit mechanism, or any case where a clinic promises proven results. The honest framing for a pet owner is: this is an experimental adjunct with a decent safety record and unproven benefit, and your money may buy hope more than outcome. For broader context on how veterinary clinics structure these offerings, see HBOT at veterinary clinics: pet therapy options.

What It Costs

Pricing for veterinary HBOT varies widely by region and facility, since it's almost always paid out of pocket. Animal-specific costs are less standardized than human pricing, but per-session fees commonly run from roughly $100 to $300, and a recommended course may involve multiple sessions, pushing total cost into the hundreds or low thousands. Pet insurance rarely covers it because of the experimental status. For a sense of how session pricing and packages work on the human side (which often informs veterinary pricing), our guide to HBOT session packages and pricing is a useful reference, and the hyperbaric chamber types: hard-shell vs soft-shell breakdown explains why chamber type matters for safety and price.

Before paying, ask the clinic three things: what specific evidence supports HBOT for your animal's condition, what chamber class and safety monitoring they use, and whether the same goal could be reached with standard care first.

Frequently Asked Questions

Is HBOT proven to work for dogs?

No. As of 2026, no randomized controlled trial has shown that HBOT improves outcomes in dogs (or cats) for any specific disease. The veterinary evidence is mostly safety data, retrospective chart reviews, and extrapolation from human and lab research. It is best considered experimental, even where clinics offer it routinely.

Is hyperbaric oxygen therapy safe for pets?

It has a reassuring short-term safety record when done properly. In a prospective trial of 230 treatments, there were no major adverse effects. The main serious risk is a seizure from CNS oxygen toxicity, which occurred in about 0.7% of sessions in the largest dog dataset, more often in dogs over six and in females. Barotrauma is also possible. Trained staff and a proper veterinary chamber matter.

What conditions do vets use HBOT for?

The most common real-world uses are neurologic injuries (about half of cases, including acute spinal cord problems), wound and tissue healing (about a third), and smaller numbers for fungal-type infections, cancer or post-radiation injury, and miscellaneous conditions. Frequent use does not mean proven benefit for these conditions.

Does pet insurance cover HBOT for animals?

Usually not. Because veterinary HBOT lacks clinical-trial support and is considered experimental, most pet insurance plans don't cover it, and owners typically pay out of pocket, often $100 to $300 per session across a multi-session course.

Is HBOT for horses backed by evidence?

Even less than for dogs. Equine HBOT data come mainly from anecdotal, case-based reports rather than controlled studies, and many equine veterinarians remain skeptical. It's used for wounds, tendon and ligament injuries, and rehabilitation, but controlled proof of benefit is missing.

This article is for general education only and is not veterinary or medical advice. Always consult a licensed veterinarian before starting any therapy for your animal.

Sources

• Common Uses and Adverse Effects of HBOT in Small Animals: Retrospective Analysis of 2,792 Treatment Sessions (Frontiers in Veterinary Science)
• Safety and Tolerability of Hyperbaric Oxygen Therapy in Cats and Dogs (J Am Anim Hosp Assoc, PMID 29757667)
• Rationale for Hyperbaric Oxygen Therapy in Traumatic Injury and Wound Care in Small Animal Veterinary Practice (PMC)
• Emerging and Adjunctive Therapies for Spinal Cord Injury Following Acute Canine Intervertebral Disc Herniation (Frontiers in Veterinary Science)
• Hyperbaric Oxygen Therapy in Equine Rehabilitation: Putting the Pressure on Disease (Vet Clin North Am Equine Pract, PMID 26898961)
• Hyperbaric Oxygen Therapy (review, Compend Contin Educ Vet, PMID 22487778)
• Veterinary Hyperbaric Oxygen Therapy: A Critical Appraisal (Clinician's Brief)
• PubMed search: hyperbaric oxygen therapy in dogs
• PubMed search: hyperbaric oxygen veterinary wound healing